Literature DB >> 20818849

Melanoma--an unlikely poster child for personalized cancer therapy.

Keiran S M Smalley, Vernon K Sondak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20818849     DOI： 10.1056/NEJMe1005370

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  35 in total

Review 1.  A brief history of melanoma: from mummies to mutations.

Authors:  Vito W Rebecca; Vernon K Sondak; Keiran S M Smalley
Journal:  Melanoma Res       Date:  2012-04       Impact factor: 3.599

2.  PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.

Authors:  John T Lee; Ling Li; Patricia A Brafford; Marcia van den Eijnden; Molly B Halloran; Katrin Sproesser; Nikolas K Haass; Keiran S M Smalley; James Tsai; Gideon Bollag; Meenhard Herlyn
Journal:  Pigment Cell Melanoma Res       Date:  2010-12       Impact factor: 4.693

Review 3.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

4.  Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells.

Authors:  R R Massaro; F Faião-Flores; V W Rebecca; S Sandri; D K Alves-Fernandes; P C Pennacchi; K S M Smalley; S S Maria-Engler
Journal:  Pharmacol Res       Date:  2017-02-14       Impact factor: 7.658

5.  Targeted therapies: Improved outcomes for patients with metastatic melanoma.

Authors:  Vernon K Sondak; Lawrence E Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2011-07-26       Impact factor: 66.675

6.  Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'?

Authors:  Spyros Retsas
Journal:  J R Soc Med       Date:  2011-06       Impact factor: 5.344

Review 7.  Therapy for metastatic melanoma: the past, present, and future.

Authors:  Laura Finn; Svetomir N Markovic; Richard W Joseph
Journal:  BMC Med       Date:  2012-03-02       Impact factor: 8.775

8.  Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells.

Authors:  Kevin J Basile; Andrew E Aplin
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

Review 9.  Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.

Authors:  Frank S Ong; Kingshuk Das; Jay Wang; Hana Vakil; Jane Z Kuo; Wendell-Lamar B Blackwell; Stephen W Lim; Mark O Goodarzi; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

10.  Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib.

Authors:  L Peuvrel; M Saint-Jean; G Quéreux; A Brocard; A Khammari; A C Knol; B Dréno
Journal:  J Neurooncol       Date:  2014-08-07       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.